Your browser doesn't support javascript.
loading
High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma.
Tang, Yuanyan; Yin, Haisen; Zhao, Xinying; Jin, Dan; Liang, Yan; Xiong, Tao; Li, Lu; Tang, Wen; Zhang, Jiangzhao; Liu, Min; Yu, Zhuojun; Liu, Huimin; Zang, Sibin; Huang, Zhiping.
Afiliação
  • Tang Y; Department of Hematology, Jingzhou Central Hospital, The Second Clinical Medical College, Yangtze University, No.60, Jingzhong Road, Jingzhou, 434020, Hubei Province, China.
  • Yin H; Department of Gastroenterology, Key Laboratory of Hubei Province for Digestive System Diseases, Renmin Hospital of Wuhan University, Wuhan, China.
  • Zhao X; Department of Hematology, Jingzhou Central Hospital, The Second Clinical Medical College, Yangtze University, No.60, Jingzhong Road, Jingzhou, 434020, Hubei Province, China.
  • Jin D; Cellyan Therapeutics Co. Ltd, Wuhan, China.
  • Liang Y; Department of Hematology, Jingzhou Central Hospital, The Second Clinical Medical College, Yangtze University, No.60, Jingzhong Road, Jingzhou, 434020, Hubei Province, China.
  • Xiong T; Department of Hematology, Jingzhou Central Hospital, The Second Clinical Medical College, Yangtze University, No.60, Jingzhong Road, Jingzhou, 434020, Hubei Province, China.
  • Li L; Cellyan Therapeutics Co. Ltd, Wuhan, China.
  • Tang W; Cellyan Therapeutics Co. Ltd, Wuhan, China.
  • Zhang J; Department of Hematology, Jingzhou Central Hospital, The Second Clinical Medical College, Yangtze University, No.60, Jingzhong Road, Jingzhou, 434020, Hubei Province, China.
  • Liu M; Department of Hematology, Jingzhou Central Hospital, The Second Clinical Medical College, Yangtze University, No.60, Jingzhong Road, Jingzhou, 434020, Hubei Province, China.
  • Yu Z; Department of Hematology, Jingzhou Central Hospital, The Second Clinical Medical College, Yangtze University, No.60, Jingzhong Road, Jingzhou, 434020, Hubei Province, China.
  • Liu H; Department of Hematology, Jingzhou Central Hospital, The Second Clinical Medical College, Yangtze University, No.60, Jingzhong Road, Jingzhou, 434020, Hubei Province, China.
  • Zang S; Department of Hematology, Jingzhou Central Hospital, The Second Clinical Medical College, Yangtze University, No.60, Jingzhong Road, Jingzhou, 434020, Hubei Province, China.
  • Huang Z; Department of Hematology, Jingzhou Central Hospital, The Second Clinical Medical College, Yangtze University, No.60, Jingzhong Road, Jingzhou, 434020, Hubei Province, China. huangzhipingdoctor@163.com.
J Exp Clin Cancer Res ; 41(1): 2, 2022 Jan 03.
Article em En | MEDLINE | ID: mdl-34980210
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: ADP-Ribosil Ciclase 1 / Antígeno de Maturação de Linfócitos B / Receptores de Antígenos Quiméricos / Mieloma Múltiplo Limite: Humans / Male Idioma: En Revista: J Exp Clin Cancer Res Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: ADP-Ribosil Ciclase 1 / Antígeno de Maturação de Linfócitos B / Receptores de Antígenos Quiméricos / Mieloma Múltiplo Limite: Humans / Male Idioma: En Revista: J Exp Clin Cancer Res Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China País de publicação: Reino Unido